Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 22

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 22
---
. This discussion and analysis contains forward-looking statements based upon
current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements
regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could
differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth
under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, and any updates
to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q and in other filings with the Securities and Exchange
Commission we may make from time-to-time.

Overview

SINTX
Technologies is an advanced ceramics company formed in December 1996 that develops and commercializes materials, components, and technologies
for medical and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄)
for musculoskeletal and antipathogenic applications. SINTX is a global leader in the research, development, and manufacturing of silicon
nitride, and its products have been implanted in humans since 2008.

SINTX
Core Business

Biomedical
Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown
to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have
been successfully implanted in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent
resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as
arthroplasty implants, foot wedges, and dental implants. More recently, in October 2025, SINTX received U.S. Food and Drug Administration
(FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive
foot and ankle surgery in the United States. These next-generation implants blend cutting-edge biomaterials science with surgical precision
and are designed to elevate standards in orthopedic procedures. SINTX silicon nitride products can be polished to a smooth and wear-resistant
surface for articulating